Date: 2013-01-07
Type of information: Development agreement
Compound: companion diagnostic tests for an investigational oncology medicine
Company: Dako (Denmark) Eli Lilly (USA)
Therapeutic area: Cancer - Oncology
Type agreement: development
Action mechanism:
Disease: undisclosed cancer
Details: Dako, an Agilent Technologies company, has entered into a master framework agreement with Eli Lilly and Company for the development of companion diagnostic tests to identify patients who may be more likely to benefit from an investigational oncology medicine currently under development by Lilly. The agreement constitutes a framework for collaboration between Dako and Lilly with a focus on the Lilly oncology pipeline.
Financial terms:
Latest news:
